Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | FBP1 | P09467 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 1/20 | 0.44 |
| ▸ | MC5R | P33032 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30721098 | 1.00 | CYP1A2 (0.49) | CYP1A2CYP3A4CYP2D6CYP2C19SMN1; SMN2 | |
| SCHEMBL30241094 | 0.81 | SMN1; SMN2 (0.36) | CYP1A2CYP3A4CYP2D6CYP2C19SMN1; SMN2 | |
| SCHEMBL5391779 | 0.78 | PTGS1 (0.55) | CYP1A2CYP3A4CYP2D6CYP2C19SMN1; SMN2 | |
| SCHEMBL6736271 | 0.78 | CYP1A2 (0.60) | CYP1A2CYP3A4CYP2D6CYP2C19SMN1; SMN2 | |
| SCHEMBL6001878 | 0.76 | PTGS1 (0.51) | CYP1A2CYP3A4CYP2D6CYP2C19SMN1; SMN2 | |
| SCHEMBL13283703 | 0.75 | PTGS1 (0.50) | CYP1A2CYP3A4CYP2D6CYP2C19SMN1; SMN2 | |
| SCHEMBL20733630 | 0.75 | PTGS1 (0.54) | CYP1A2CYP3A4CYP2D6CYP2C19SMN1; SMN2 | |
| SCHEMBL347497 | 0.75 | SMN1; SMN2 (0.54) | CYP1A2CYP3A4CYP2D6CYP2C19SMN1; SMN2 | |
| SCHEMBL11684240 | 0.74 | SMN1; SMN2 (0.56) | CYP1A2CYP3A4CYP2D6CYP2C19SMN1; SMN2 | |
| SCHEMBL3938450 | 0.74 | PTGS1 (0.50) | CYP1A2CYP3A4CYP2D6CYP2C19SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150376085-A1 | ANTHRACENE COMPOUND, METHOD FOR PREPARING THE SAME, USE THEREOF AND ORGANIC LIGHT EMITTING DEVICE | BOE TECHNOLOGY GROUP CO., LTD. (CN) | 2015-12-31 | — | — | US | claimed |
| CN-113563323-A | Benzothiazolyl biaryl compounds, preparation method and application | 上海凌达生物医药有限公司 | 2021-10-29 | — | — | CN | disclosed |
| CN-108530473-A | With the compound of amyloid beta specific binding | 南京中硼联康医疗科技有限公司 | 2018-09-14 | — | — | CN | disclosed |
| CN-108440584-A | It is used to prepare the preparation method of the intermediate of the compound specifically bound with amyloid beta | 南京中硼联康医疗科技有限公司 | 2018-08-24 | — | — | CN | disclosed |
| CN-108395446-A | With the preparation method of the compound of amyloid beta specific binding | 南京中硼联康医疗科技有限公司 | 2018-08-14 | — | — | CN | disclosed |
| CN-108276435-A | It is used to prepare the preparation method of the intermediate of the compound specifically bound with amyloid beta | 南京中硼联康医疗科技有限公司 | 2018-07-13 | — | — | CN | disclosed |
| CN-108239100-A | It is used to prepare compound, the preparation method and applications of the compound specifically bound with amyloid beta | 南京中硼联康医疗科技有限公司 | 2018-07-03 | — | — | CN | disclosed |
| CN-108187044-A | For eliminating the neutron capture treatment system of amyloid beta | 南京中硼联康医疗科技有限公司 | 2018-06-22 | — | — | CN | disclosed |
| CN-106674265-B | Compounds that specifically bind to β amyloid | 南京中硼联康医疗科技有限公司 | 2018-03-09 | — | — | CN | disclosed |
| CN-106730414-B | Neutron capture therapy system for eliminating beta amyloid | 南京中硼联康医疗科技有限公司 | 2017-10-10 | — | — | CN | disclosed |
| CN-106730414-A | Neutron capture therapy system for eliminating beta amyloid | 南京中硼联康医疗科技有限公司 | 2017-05-31 | — | — | CN | disclosed |
| CN-106674265-A | Compounds that specifically bind to amyloid beta | 南京中硼联康医疗科技有限公司 | 2017-05-17 | — | — | CN | disclosed |
| US-20150376085-A1 | ANTHRACENE COMPOUND, METHOD FOR PREPARING THE SAME, USE THEREOF AND ORGANIC LIGHT EMITTING DEVICE | BOE TECHNOLOGY GROUP CO., LTD. (CN) | 2015-12-31 | — | — | US | disclosed |
| CN-105078978-A | Heterocyclic compounds and uses thereof | INTELLIKINE LLC | 2015-11-25 | — | — | CN | disclosed |
| CN-102573846-B | Heterocyclic compounds and their use | INTELLIKINE, INC. (US) | 2015-10-07 | — | — | CN | disclosed |
| CN-103130741-A | Organic semiconductor material containing naphthyl anthracene and preparation method and application thereof | OCEANS KING LIGHTING SCIENCE | 2013-06-05 | — | — | CN | disclosed |
| CN-102573846-A | Heterocyclic compounds and their use | INTELLIKINE INC | 2012-07-11 | — | — | CN | disclosed |
| EP-1444981-A1 | INTRACELLULAR CALCIUM CONCENTRATION INCREASE INHIBITORS | Mikoshiba, Katsuhiko (JP) | 2004-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376085-A1 | ANTHRACENE COMPOUND, METHOD FOR PREPARING THE SAME, USE THEREOF AND ORGANIC LIGHT EMITTING DEVICE | CYP2C9, AHR, AOC2 | CYP1A2 21/4885CYP3A4 68/4885CYP2D6 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.